IPP Bureau
Robert M. Davis is the new Chairman of Merck
By IPP Bureau - October 27, 2022
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
ERES IV acquires a majority stake in Oncodesign Services
By IPP Bureau - October 27, 2022
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Laurus Labs planning Rs. 2,000 Cr Capex
By IPP Bureau - October 27, 2022
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
CEPI and SK bioscience partner to advance mRNA vaccine technology
By IPP Bureau - October 26, 2022
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData
By IPP Bureau - October 26, 2022
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Quizartinib granted priority review in the U.S.
By IPP Bureau - October 26, 2022
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
USFDA approves Imjudo in combination with Imfinzi for liver cancer
By IPP Bureau - October 26, 2022
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Novartis maintains growth momentum; Confirms FY’22 Group guidance
By IPP Bureau - October 26, 2022
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
By IPP Bureau - October 26, 2022
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Zydus receives final approval from USFDA for Micafungin for Injection
By IPP Bureau - October 26, 2022
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Biocon Biologics insulins facility in Malaysia receives EU GMP Certification
By IPP Bureau - October 26, 2022
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Lupin launches Paliperidone Extended-Release Tablets in US
By IPP Bureau - October 24, 2022
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Aster DM Healthcare to acquire Sr Sainatha Multispeciality Hospitals
By IPP Bureau - October 24, 2022
Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr
By IPP Bureau - October 23, 2022
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr
By IPP Bureau - October 23, 2022
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
